People: Board member appointed at incident management firm; Trio of hires at solicitors; New CEO at medical devices company; and more
Incident Management specialist FMG has appointed Domenico Mariconda to the role of Sales and Marketing Director.
Mariconda joins the Huddersfield firm with industry knowledge and expertise to complement the existing board, following a 20-year career in blue chip sales and marketing organisations.
Mark Chessman, CEO at FMG, said, “This is an exciting appointment for FMG. As market-leader, we recognise the need to maximise our experience, flexibility and agility to continually deliver an unrivalled product and service offering to customers. Domenico is a welcome addition to the team. He is vastly experienced and will bring a new dimension to FMG as we expand the company’s reach and develop the business proposition for the future.”
Maricondo has held senior roles within companies including Octo Telematics, Lloyds Banking Group and Lex Autolease. He joins FMG from Vodafone Automotive where he was Sales Director for the Northern Europe and North America.
:::
Hawkswell Kilvington, the niche firm of construction and engineering solicitors, has made a trio of further hires.
Solicitors Matthew Leonard, Jonathan Robson and Dominic Canning have all joined the Wakefield firm, and will focus on resolving construction disputes through adjudication, litigation, arbitration and mediation. Leonard has joined from Irwin Mitchell, Robson from Emsleys Solicitors and Canning from Plexus Law.
Daniel Silberstein, a partner at Hawkswell Kilvington, said “I am delighted that Matthew, Jonathan and Dominic have all chosen to join us. They are all excellent solicitors and I have no doubt that they quickly settle in and become valuable additions to our renowned team.”
:::
Tissue Regenix Group, the regenerative medical devices company based in Leeds, has appointed Steve Couldwell, as chief executive with immediate effect.
Couldwell has been in the position of non- executive director since July 2013 and has over 25 years’ experience in the pharmaceutical and medical device industry, with a track record of delivering revenue and profit growth.
Most recently he was chief operating officer at Global Sanofi Biosurgery , delivering strong double digit growth internationally for three consecutive years. Prior to this Couldwell held a number of roles at Smith & Nephew.
Couldwell, said: “Since being appointed to the board in 2013 I have been impressed with the great commercial potential of our dCELL platform. The recent acquisition of CellRight Technologies has increased the market potential and provided a highly complementary product range in the $1.7bn US bone graft and substitute market. I am delighted to be appointed CEO and look forward to leading the Group through the integration of CellRight and expansion of commercial activities as we execute our commercial strategy and grow our market share throughout the US and the rest of the world.”
John Samuel, chairman, Tissue Regenix, added: “The Board and I are delighted to welcome Steve as the Group’s new CEO. He has an exceptional track record of growing businesses and the Board firmly believes that Steve has the required skillset and experience to guide the Group along the pathway to profitability. Alongside this, Steve has an in-depth knowledge of the Group thanks to his years as a non-executive director making him an ideal candidate for this position.”
